Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.
2.

Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.

Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL.

Endocr Relat Cancer. 2003 Jun;10(2):179-86. Review.

3.

[Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].

Viallard JF, Lacombe F, Belloc F, Pellegrin JL, Reiffers J.

Cancer Radiother. 2001 Apr;5(2):109-29. Review. French.

PMID:
11355576
4.

Aberrant cell cycle regulation in cervical carcinoma.

Kim YT, Zhao M.

Yonsei Med J. 2005 Oct 31;46(5):597-613. Review.

5.

Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta.

Ravitz MJ, Wenner CE.

Adv Cancer Res. 1997;71:165-207. Review.

PMID:
9111866
6.

The role of Cdc25A in the regulation of cell proliferation and apoptosis.

Shen T, Huang S.

Anticancer Agents Med Chem. 2012 Jul;12(6):631-9. Review.

7.

Cyclin D-dependent kinases, INK4 inhibitors and cancer.

Ortega S, Malumbres M, Barbacid M.

Biochim Biophys Acta. 2002 Mar 14;1602(1):73-87. Review.

PMID:
11960696
8.

Role of cyclin-dependent kinases and their inhibitors in cellular differentiation and development.

Chellappan SP, Giordano A, Fisher PB.

Curr Top Microbiol Immunol. 1998;227:57-103. Review. No abstract available.

PMID:
9479826
9.

Estrogen and progestin regulation of cell cycle progression.

Sutherland RL, Prall OW, Watts CK, Musgrove EA.

J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):63-72. Review.

PMID:
10819505
10.

Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks.

Adams PD.

Biochim Biophys Acta. 2001 Mar 21;1471(3):M123-33. Review.

PMID:
11250068
11.

Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.

Roskoski R Jr.

Pharmacol Res. 2016 May;107:249-275. doi: 10.1016/j.phrs.2016.03.012. Epub 2016 Mar 16. Review.

PMID:
26995305
12.

Tumor suppressors and oncogenes in cellular senescence.

Bringold F, Serrano M.

Exp Gerontol. 2000 May;35(3):317-29. Review.

PMID:
10832053
13.

Cdc2: a monopotent or pluripotent CDK?

Hu X, Moscinski LC.

Cell Prolif. 2011 Jun;44(3):205-11. doi: 10.1111/j.1365-2184.2011.00753.x. Review.

PMID:
21535261
14.
15.

Driving the cell cycle to cancer.

Malumbres M, Hunt SL, Sotillo R, Martín J, Odajima J, Martín A, Dubus P, Ortega S, Barbacid M.

Adv Exp Med Biol. 2003;532:1-11. Review.

PMID:
12908544
16.

Roles of cyclin-dependent kinase inhibitors: lessons from knockout mice.

Kiyokawa H, Koff A.

Curr Top Microbiol Immunol. 1998;227:105-20. Review. No abstract available.

PMID:
9479827
17.

Cell division cycle alterations and human tumors.

Della Ragione F, Borriello A, Della Pietra V, Cucciolla V, Oliva A, Barbarisi A, Iolascon A, Zappia V.

Adv Exp Med Biol. 1999;472:73-88. Review. No abstract available.

PMID:
10736618
18.

Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Liang J, Slingerland JM.

Cell Cycle. 2003 Jul-Aug;2(4):339-45. Review.

PMID:
12851486
19.

p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis.

Matsuda Y, Ichida T.

Med Mol Morphol. 2006 Dec;39(4):169-75. Epub 2006 Dec 21. Review.

PMID:
17187177
20.

Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors.

Lu Z, Hunter T.

Cell Cycle. 2010 Jun 15;9(12):2342-52. Epub 2010 Jun 15. Review.

Supplemental Content

Support Center